Oral Fexinidazole Dosing Regimens for the Treatment of Adults With Chronic Indeterminate Chagas Disease

Screening Criteria: * Signed, written informed consent form * Age \>18 to \< 60 years * Weight \> 50 kg to \< 90 kg * Diagnosis of T. cruzi infection by: * Conventional serology (a minimum of two positive tests \[Conventional ELISA, Recombinant Elisa, Chemiluminescence Immunoassays and/or Indirect Immunofluorescence (IIF)\] * Ability to comply with all protocol specified tests and visits and have a permanent address * No signs and/or symptoms of the chronic cardiac and/or digestive form of Chagas Disease (CD) (as per study operating procedures) * No personal history of mental disability or suicidal tendencies * No acute or chronic health conditions, that in the opinion of the PI, may interfere with the efficacy and/or safety evaluation of the trial drug (such as acute infections, history of HIV infection, liver, and renal disease requiring treatment) * No formal contraindication to FEXI (according to the latest available Investigator's Brochure) * No history of hypersensitivity, allergic, or serious adverse reactions to any of the "nitro-imidazoles" compound, and/or its components * No history of CD treatment with BZN, FEXI or Nifurtimox (NFX) at any time in the past * No history of alcohol abuse or any other drug addiction (as per Study Manual of Operations) * No condition that prevents patient from taking oral medication * No concomitant medication with drug known risk of Torsade de Pointe, according AZCERT Scientific Publications and Sudden Arrhythmia Death Syndromes Foun…